Figures computed from official regulatory filings — .
Analysttarget 41.07 USD (+57%) · consensus 4.86/5 · 14 buy · 0 hold · 0 sell
Ownershipinsiders 1.31% · institutions 98.97% · short 10.4% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Zymeworks BC Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
5 buys41 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Josephson Neil | Sell | $20K | SEC | ||
| Josephson Neil |
| ExerciseD (derivative) |
| n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) |
| SEC |
| Josephson Neil | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Moore Paul Andrew | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Josephson Neil | Award | $6.9K | SEC |
| Klompas Neil A | Award | $6.9K | SEC |
| Klompas Neil A | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klompas Neil A | Sell | $20.5K | SEC |
| Klompas Neil A | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klompas Neil A | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klompas Neil A | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Josephson Neil | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Josephson Neil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Josephson Neil | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Astle Christopher | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Klompas Neil A | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Josephson Neil | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Galbraith Kenneth | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Josephson Neil | Buy | $20K | conv 76First in 12mo | SEC |
| Josephson Neil | Buy | $51.4K | conv 86First in 12mo | SEC |
| Polverino Anthony J. | Award | $1K | SEC |
| Klompas Neil A | Award | $3.9K | SEC |
| Josephson Neil | Award | $906.1 | SEC |
| Josephson Neil | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Josephson Neil | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |